CSL Research Acceleration Initiative
Applications close 12\textsuperscript{th} March 2021

CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organisations.

The 2021 Research Acceleration Initiative will focus on research proposals that align with a CSL Therapeutic Area and are amenable to or include a Modality as illustrated below. Please see over page for specific Focus Areas.

Successful applicants will receive up to USD 200k p.a. for up to 2 years (max USD 400k funding).

Researchers who wish to apply are required to submit a 300 word online pre-application by 12\textsuperscript{th} March 2021 via the following link
Shortlisted applicants will then be invited to submit a detailed proposal in April.

Interested researchers are invited to join an online information session to learn more. Times and links will be announced separately by your Research or Innovation Office.

Please note: only Researchers from registered Institutions are eligible to apply.
CSL Research Acceleration Initiative

Focus Areas
CSL is seeking applications in the following Focus Areas:

**Autoimmune diseases**
Novel biologic targets/therapeutics or strategies to understand pathomechanisms of: Sjögren’s syndrome, Systemic sclerosis, SLE, Pemphigus vulgaris, Hidradenitis suppurativa, Dermatomyositis, other rare rheumatological/dermatological conditions

**Inflammation**
Novel strategies to modulate the immune system to treat inflammatory diseases (including neuroinflammation e.g. CIDP)

**Next generation IVIG / alternatives to plasma-derived IVIG**

**Sickle cell disease**
Prophylactic therapies to reduce vaso-occlusive crises and chronic vasculopathy

**Ischemic and hemorrhagic stroke**
Novel biologic targets/therapeutics or strategies to understand pathomechanisms

Focus on neuro- and thrombo-inflammation/novel thrombolysics

Biomarker/Omics approaches for patient stratification and drug discovery

**Hemophilia**
*In vivo* gene-editing and technologies for liver targeted delivery

**Interstitial lung diseases** (progressive, fibrosing)
Novel biologic targets/therapeutics

**Biomarker/Omics approaches for patient stratification and drug discovery**

**Healthepa**
*In vivo* gene-editing and technologies for liver targeted delivery

**Alpha-1 antitrypsin deficiency**
In *vivo* gene-editing and technologies for liver targeted delivery

**Rare lipid disorders** (e.g. Familial hypercholesterolemia, Familial chylomicronemia)
In *vivo* gene-editing and technologies for liver targeted delivery

**Severe forms of atherosclerosis**
Novel biologic targets/therapeutics or strategies to understand pathomechanisms

**Acute respiratory distress syndrome**
Novel biologic targets/therapeutics

**Biomarker/Omics approaches for patient stratification and drug discovery**

**Myocarditis**
Novel biologic targets/therapeutics

**Novel animal and human disease models**

**Hematopoietic stem cell transplants**
Strategies to improve efficacy/safety, including inducing stem cell mobilisation, reducing toxicity of BM conditioning, improvement of engraftment

**Tolerance**
(Solid organ transplant/HSCT)
Novel strategies or biologics to induce tolerance (T regs, T cell anergy and/or tolerogenic DCs)

**Graft vs host disease**
Novel biologic targets/therapeutics to modulate the immune response for treatment and prevention

**Acute rejection** (Antibody-mediated rejection)
Novel biologic targets/therapeutics to modulate the immune response

CSL is also interested in new uses for our existing products. If you have a proposal in this area, please e-mail RAI@csl.com.au to discuss.